NRx Pharmaceuticals to Report Q1 2025 Financial Results Following Strategic Acquisition in Psychedelic Research

NRx Pharmaceuticals Inc. (NASDAQ: NRXP) is set to disclose its first quarter 2025 financial results on Thursday, May 15, post-market closure. The announcement will be followed by a conference call and webcast at 4:30 p.m. ET, available through the company's investor relations site or via phone. This financial update is timely, coming on the heels of NRx's subsidiary, HOPE Therapeutics, finalizing an agreement to acquire Kadima Neuropsychiatry Institute, a leading clinic in La Jolla, California, renowned for its pioneering work in psychedelic and neuroplastic research.

The acquisition of Kadima, a profitable entity specializing in treatments for conditions such as suicidal depression and PTSD, is poised to serve as the blueprint for HOPE Therapeutics' national clinic expansion. This strategic move underscores NRx Pharmaceuticals' commitment to advancing treatments for central nervous system disorders through its NMDA platform, including the development of NRX-101, an FDA-designated Breakthrough Therapy for suicidal treatment-resistant bipolar depression and chronic pain.

NRx Pharmaceuticals is also progressing with a New Drug Application for NRX-100, a preservative-free IV ketamine formulation aimed at treating suicidal depression, leveraging data from clinical trials and French health authorities. The company's initiatives, including Fast Track Designation by the U.S. FDA for ketamine development, highlight its potential to revolutionize treatment paradigms for acute suicidality and chronic pain without reliance on opioids.

For more details on the Kadima acquisition, the press release can be accessed here. NRx Pharmaceuticals continues to forge ahead in the biopharmaceutical sector, with its innovative approaches to CNS disorders and strategic acquisitions positioning it as a key player in the psychedelic and neuroplastic research arena.